Guest Symposium at ARCEDI Biotech ApS

Author Archives: WebMast

Guest Symposium at ARCEDI Biotech ApS

read more

27-11-2017 PRESS RELEASE

ARCEDI BIOTECH TO PRESENT AT FIFTH ANNUAL ADVANCES IN PRENATAL MOLECULAR DIAGNOSTICS CONFERENCE – Additional Presentations and Panel Discussions Highlight Advances in Cell-Based Non-Invasive Prenatal Testing – Vejle, Denmark, November 27, 2017 – ARCEDI Biotech ApS, a company developing technologies for rare fetal cell detection for use in prenatal diagnostic applications, today announced that Ripudaman […]

read more

13-11-2017 PRESS RELEASE

ARCEDI BIOTECH ANNOUNCES LAUNCH OF FIRST AND ONLY NON-INVASIVE PRENATAL TESTING BASED ON FETAL CELLS IN MATERAL BLOOD IN DENMARK – Comparative Non-Invasive Alternative to Invasive “Gold-Standard” Testing – Vejle, Denmark, November 13, 2017 – ARCEDI Biotech ApS, a company developing technologies for rare fetal cell detection for use in prenatal diagnostic applications, today announced […]

read more

6-11-17 PRESSEMEDDELELSE (Dansk)

PRESSEMEDDELELSE Ny og lovende fosterdiagnostik er mere skånsom for gravide I fremtiden vil det måske blive muligt for gravide at undgå en moderkageprøve. En simpel blodprøve vil kunne give den samme detaljerede viden om fosteret. Det viser ny forskning fra Aarhus Universitetshospital og det danske firma Arcedi Biotech. Mange gravide bliver bekymrede, hvis de får […]

read more

BREAKING – Simpel blodprøve kan erstatte moderkageprøve hos gravide

06. nov. 2017, 11:27 af Rizau Ny og lovende fosterdiagnostik er mere skånsom over for gravide, viser ny forskning. I fremtiden bliver det måske muligt for gravide at undgå en moderkageprøve. En simpel blodprøve kan give den samme detaljerede viden om fosteret. Det viser ny forskning fra Aarhus Universitetshospital og det danske firma Arcedi Biotech. […]

read more

ARCEDI Biotech Readying Cell-Based NIPT for Commercialization as Clinical Studies Continue (GenomeWeb)

Oct 30, 2017 Julia Karow NEW YORK (GenomeWeb) – Arcedi Biotech of Denmark has been collaborating with six Danish hospitals to clinically validate its technology for isolating circulating fetal cells from maternal blood and analyzing their DNA for noninvasive prenatal diagnostics. Arcedi hopes to commercialize the technology in the near future through a large diagnostic […]

read more

On the road to replacing invasive testing with cell‐based NIPT: Five clinical cases with aneuploidies, microduplication, unbalanced structural rearrangement, or mosaicism

Objective: Trophoblastic fetal cells harvested from maternal blood have the capacity to be used for copy number analyses in a cell‐based non‐invasive prenatal test (cbNIPT). Potentially, this will result in increased resolution for detection of subchromosomal aberrations due to high quality DNA not intermixed with maternal DNA. We present 5 selected clinical cases from first […]

read more

12-10-17 PRESS RELEASE

ARCEDI BIOTECH ANNOUNCES PUBLICATION HIGHLIGHTING SUCCESS OF CUTTING-EDGE CELL-BASED NONINVASIVE PRENATAL TESTING TO DETECT ANEUPLOIDY AND SUBCHROMOSOMAL ABNORMALITIES IN FIRST TRIMESTER PREGNANCIES – Preliminary Results Identical to Invasive “Gold-Standard” Testing – Vejle, Denmark, October 12, 2017 – ARCEDI Biotech ApS, a company developing technologies for rare fetal cell detection for use in prenatal diagnostic applications, […]

read more

A Noninvasive Future – Prenatal Genetic Testing Looks to Single-Cell Methods as the Next Frontier

ClinicalOmics By Helen Albert|August 2017 Prenatal genetic testing has advanced enormously over the last few decades. Amniocentesis and chorionic villus sampling (CVS) have been performed to diagnose fetal abnormalities for many years, but these tests are invasiveand not without problems. The risk for miscarriage is low (approximately 1 in 1000 for amniocentesis and 1 in 500 […]

read more

Fetal cells in maternal blood for prenatal diagnosis: a love story rekindled

Biomark Med. 2017 Jun 15 Singh R, Hatt L, Ravn K, Vogel I, Petersen OB, Uldbjerg N, Schelde P For decades it has been common knowledge that some cells from the developing fetus make their way into maternal circulation, and that this process starts in the early weeks of first trimester. Naturally, when alternative technologies for prenatal diagnosis were being explored, the use of […]

read more